Betalucil is metoprolol succinate extended-release tablets or metoprolol tartrate tablets, which can be used to treat high blood pressure and angina pectoris.
The main ingredient of Metoprolol Perfolate Extended-Release Tablets is Metoprolol Succinate, which can be used to treat hypertension, angina pectoris, and chronic heart failure presenting with abnormal left ventricular systolic function of the stabilized left ventricle.
Adverse reactions can occur in blood and lymphatic system diseases, such as thrombocytopenia; psychiatric category, such as depression, confusion, neuroticism, nightmares, etc.; central and peripheral nervous system, such as fatigue, sensory abnormalities, headache, etc.; cardiac organ disease, such as bradycardia, fainting, coldness of limbs, etc..
This drug is contraindicated in case of cardiogenic shock, atrioventricular block of II or III degree, sick sinus node syndrome, hypersensitivity to any of the components in this product or other beta-blockers, etc.
Metoprolol tartrate tablets are commonly used in the treatment of hypertension, myocardial infarction, angina pectoris, aortic coarctation, hypertrophic cardiomyopathy, hyperthyroidism, arrhythmia and cardiac neurosis.
Adverse reactions include circulatory system, such as cold extremities, palpitations (rapid heartbeat, often accompanied by panic); gastrointestinal system, such as abdominal pain, vomiting, constipation, etc.; neurological system, such as sleep disorders, etc.; headache and dizziness. The drug is contraindicated in the presence of cardiogenic shock, atrioventricular block of the second or third degree, sick sinus node syndrome, patients with decompensated heart failure.
The drug needs to be applied rationally according to the doctor’s instructions.